A PHASE IIIB/IV, MULTICENTER, RANDOMIZED, OPEN-LABEL, TWO-ARM STUDY TO INVESTIGATE THE EFFICACY, SAFETY, AND DURABILITY OF FARICIMAB ADMINISTERED UP TO EVERY 24 WEEKS IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (CONSTANCE)_MR45638